

# Cleaved PARP (Asp214) (H8) rabbit mAb

[www.abwizbio.com](http://www.abwizbio.com)

Support: [info@abwizbio.com](mailto:info@abwizbio.com)

Order: [sales@abwizbio.com](mailto:sales@abwizbio.com)


**Catalog:** #2331

**Store at:** -20°C


*For Research Use Only. Not For Use In Diagnostic Procedures.*

Applications	Detection	Clonality	Isotype
Flow Cytometry, WB	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk

<b>Format:</b>	Unconjugated
<b>Cross Reactivity:</b>	Predicted to work with mouse, rat and other homologues.
<b>Formulation:</b>	1X PBS, 0.02% NaN <sub>3</sub> , 50% Glycerol, 0.1% BSA
<b>Preparation:</b>	Protein A+G
<b>Reactivity:</b>	Human
<b>Recommended Usage:</b>	1µg/mL - 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.
<b>Immunogen:</b>	A synthetic peptide corresponding to residues surrounding Asp214 of human PARP
<b>Description:</b>	Poly-ADP-ribose polymerase 1 (PARP-1), is a substrate of caspase-3 and caspase-7, both of which play a dominant role in apoptosis. PARP is cleaved into 89 and 24 kDa fragments at Asp214 (1). The detection of these fragments is used as an indicator of caspase activation and apoptosis induction for many cell lines. Under normal conditions, PARP aids in the detection and repair of DNA damage (2). With 1-2 million copies per nucleus, PARP is also involved in poly (ADP-ribosyl)ation, a post-translational protein modification mechanism used to modify chromatin structure and regulate transcription. Decreased PARP activity has been shown to lead to loss of memory and neuronal cell death (3).
<b>References:</b>	<ol style="list-style-type: none"><li>1. Bressenot A, et al., (2009) J Histochem Cytochem. 57: 289-300.</li><li>2. Chaitanya GV, Alexander JS, and Babu, PP. (2010) Cell Comm Signal. 8:31.</li><li>3. Kraus WL, and Lis JT. (2003) Cell. 113:677-683.</li></ol>




Western blot analysis of HeLa cell extract untreated or treated with Staurosporine using Cleaved PARP (Asp214) antibody PARP-H8 at 0.001 ug/mL. Cat. #2331.



	IgG	Treatment	Peptide Block	Median : BL1-A
	H8	Staur	Control peptide	10765
	H8	Ctrl	Control peptide	616
	H8	Staur	PARP	347
	H8	Ctrl	PARP	543
	H8	Staur	-	11054
	H8	Ctrl	-	659
	2' only	Ctrl		499


Peptide blocking flow cytometric analysis of SK.N.MC cells secondary antibody only negative control (light blue) or untreated (red) or treated with staurosporine (green) or untreated and blocked with immunogen peptide (black) or treated and blocked with immunogen peptide (gold) or untreated and blocked with irrelevant peptide (dark blue) or treated and blocked with irrelevant peptide (purple) using PARP Cleaved Asp214 antibody PARP-H8 at 0.1  $\mu\text{g/mL}$ . Cat. #2331.



Flow cytometric analysis of SK.N.MC cells unstained untreated cells as negative control (blue) or stained untreated (red) or treated with staurosporine (green) using PARP Cleaved (Asp214) antibody PARP-H8 at 0.1  $\mu\text{g/mL}$ . Cat. #2331.

## Abwiz Cat. #2331

**0.001** µg/mL



**+**

**-**


**Cleaved PARP  
(D214)**

**Staurosporine**

## Company C

**0.05** µg/mL

(recommended conc.)




**+**

**-**

Western blot analysis of HeLa cell extract untreated or treated with staurosporine using 0.001 µg/mL Cleaved PARP (Asp214) antibody PARP-H8 Cat. #2331 or Company C antibody at 0.05 µg/mL (manufacturer's recommended concentration) developed using the same exposure.

**Abwiz Cat. #2331**


**0.1 µg/mL**



**PARP, Cleaved (D214)**

**Company C**

**0.1 µg/mL**  
**(recommended conc.)**



**PARP, Cleaved (D214)**

Flow cytometric analysis of SK.N.MC cells secondary antibody only negative control (blue) or untreated (red) or treated with staurosporine (green) using PARP, Cleaved Asp214 antibody PARP-H8 (Abwiz Cat. #2331) or Company C antibody at 0.1 µg/mL (manufacturer's recommended concentration).